Clinical Oral Investigations

, Volume 23, Issue 3, pp 1415–1423 | Cite as

Clinical and diagnostic significance of serum immunoglobulin A rheumatoid factor in primary Sjogren’s syndrome

  • Kyung-Ann Lee
  • Kyoung-Woon Kim
  • Bo-Mi Kim
  • Ji-Yeon Won
  • Han-Ah Kim
  • Hee-Won Moon
  • Hae-Rim Kim
  • Sang-Heon LeeEmail author
Original Article



The aim of this study was to investigate the diagnostic accuracy of rheumatoid factor (RF) isotype for the detection of primary Sjogren’s syndrome (pSS) and evaluate the clinical and serological associations of immunoglobulin (Ig) A RF in patients with pSS.

Materials and methods

RF levels were measured in 77 and 37 patients with pSS and idiopathic sicca symptoms, respectively, using ELISA and analysed with respect to clinical and laboratory disease characteristics. Receiver operating characteristic curves were used to determine and compare the diagnostic accuracy of IgA RF with other diagnostic tests.


Serum levels of IgA RF were significantly higher in patients with pSS than in those with idiopathic sicca symptoms. IgA RF showed sensitivity, specificity, positive, and negative predictive values of 83.1, 78.4, 88.9, and 69.0%, respectively, for pSS diagnosis. IgA RF was associated with xerostomia, severe sialoscintigraphic grade, low unstimulated salivary flow rate (USFR), antinuclear antibody, high IgG and IgM/G RF levels, and low C3 levels in patients with pSS. IgA RF titres had positive correlations with sialoscintigraphic grade and IgG and IgG/M RF levels and had negative correlations with USFR and C3 levels.


Our findings confirmed the potential of IgA RF to distinguish pSS from idiopathic sicca symptoms. The presence of IgA RF in patients with pSS was associated with significantly worse exocrine function and active serologic profile. No association between IgA RF and extra-glandular manifestations was noted.

Clinical relevance

IgA RF should be the predictive and diagnostic marker in patients with pSS.


Sjogren’s syndrome Rheumatoid factor IgA rheumatoid factor Diagnosis Exocrine function Extra-glandular manifestations 



This work was funded by the Konkuk University Medical Center Research Grant 2016.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all the individual participants included in the study.


  1. 1.
    Kim KS, Kim HS (2016) Successful treatment of sensorineural hearing loss in Sjogren’s syndrome with corticosteroid. Korean J Intern Med 31(3):612–615. CrossRefGoogle Scholar
  2. 2.
    Carvajal Alegria G, Guellec D, Devauchelle-Pensec V, Saraux A (2015) Is there specific neurological disorders of primary Sjogren’s syndrome? Joint Bone Spine 82(2):86–89. CrossRefGoogle Scholar
  3. 3.
    Rischmueller M, Tieu J, Lester S (2016) Primary Sjogren’s syndrome. Best Pract Res Clin Rheumatol 30(1):189–220. CrossRefGoogle Scholar
  4. 4.
    Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35(6):727–734. CrossRefGoogle Scholar
  5. 5.
    Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. CrossRefGoogle Scholar
  6. 6.
    Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A, De Vita S, Gerli R, Valesini G, Bombardieri S (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 53(5):839–844.
  7. 7.
    Bournia VK, Vlachoyiannopoulos PG (2012) Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 39(1–2):15–26. CrossRefGoogle Scholar
  8. 8.
    Lim SA, Nam S, Kwok SK, Park SH, Chung SH (2015) Serologic markers are associated with ocular staining score in primary Sjogren syndrome. Cornea 34(11):1466–1470. CrossRefGoogle Scholar
  9. 9.
    Youinou P, Pers JO (2015) Primary Sjogren’s syndrome at a glance today. Joint Bone Spine 82(2):75–76. CrossRefGoogle Scholar
  10. 10.
    Atkinson JC, Travis WD, Slocum L, Ebbs WL, Fox PC (1992) Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary Sjogren’s syndrome. Arthritis Rheum 35(11):1368–1372CrossRefGoogle Scholar
  11. 11.
    Muller K, Oxholm P, Mier-Madsen M, Wiik A (1989) Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjogren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol 18(1):29–31CrossRefGoogle Scholar
  12. 12.
    Peen E, Mellbye OJ, Haga HJ (2009) IgA rheumatoid factor in primary Sjogren’s syndrome. Scand J Rheumatol 38(1):46–49. CrossRefGoogle Scholar
  13. 13.
    Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76(1):9–16. CrossRefGoogle Scholar
  14. 14.
    Navazesh M, Kumar SK (2008) Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 139(Suppl):35s–40sCrossRefGoogle Scholar
  15. 15.
    Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dorner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, K LS, Smolen J, Laque RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C (2015) EULAR Sjogren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1(1):e000022. CrossRefGoogle Scholar
  16. 16.
    Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, Del Papa N, De Vita S, Epis O, Franceschini F, Gerli R, Govoni M, Bongi SM, Maglione W, Migliaresi S, Montecucco C, Orefice M, Priori R, Tavoni A, Valesini G (2007) Sjogren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 56(7):2223–2231. CrossRefGoogle Scholar
  17. 17.
    Schall GL, Anderson LG, Wolf RO, Herdt JR, Tarpley TM Jr, Cummings NA, Zeiger LS, Talal N (1971) Xerostomia in Sjogren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA 216(13):2109–2116CrossRefGoogle Scholar
  18. 18.
    Dorner T, Egerer K, Feist E, Burmester GR (2004) Rheumatoid factor revisited. Curr Opin Rheumatol 16(3):246–253CrossRefGoogle Scholar
  19. 19.
    ter Borg EJ, Risselada AP, Kelder JC (2011) Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren’s syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum 40(6):547–551. CrossRefGoogle Scholar
  20. 20.
    Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L (2008) Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87(4):210–219. CrossRefGoogle Scholar
  21. 21.
    Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jauberteau MO, Hachulla E, Vidal E, Hatron PY (2010) Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 9(9):595–599. CrossRefGoogle Scholar
  22. 22.
    Martel C, Gondran G, Launay D, Lalloue F, Palat S, Lambert M, Ly K, Loustaud-Ratti V, Bezanahary H, Hachulla E, Jauberteau MO, Vidal E, Hatron PY, Fauchais AL (2011) Active immunological profile is associated with systemic Sjogren’s syndrome. J Clin Immunol 31(5):840–847. CrossRefGoogle Scholar
  23. 23.
    Fragkioudaki S, Mavragani CP, Moutsopoulos HM (2016) Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine 95(25):e3766. CrossRefGoogle Scholar
  24. 24.
    Nocturne G, Virone A, Ng WF, Le Guern V, Hachulla E, Cornec D, Daien C, Vittecoq O, Bienvenu B, Marcelli C, Wendling D, Amoura Z, Dhote R, Lavigne C, Fior R, Gottenberg JE, Seror R, Mariette X (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren’s syndrome. Arthritis Rheumatol 68(4):977–985. CrossRefGoogle Scholar
  25. 25.
    Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48(10):2741–2749. CrossRefGoogle Scholar
  26. 26.
    Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62(5):427–430CrossRefGoogle Scholar
  27. 27.
    Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, Rygg M, Zak M, Ronnelid J (2014) Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J 12(22):22. CrossRefGoogle Scholar
  28. 28.
    Ramos-Casals M, Brito-Zeron P, Perez DELM, Diaz-Lagares C, Bove A, Soto MJ, Jimenez I, Belenguer R, Siso A, Muxi A, Pons F (2010) Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren’s syndrome. J Rheumatol 37(3):585–590. CrossRefGoogle Scholar
  29. 29.
    Güne S, Yilmaz S, Karalezli A, Aktas A (2010) Quantitative and visual evaluation of salivary and thyroid glands in patients with primary Sjogren’s syndrome using salivary gland scintigraphy: relationship with clinicopathological features of salivary, lacrimal and thyroid glands. Nucl Med Commun 31(7):666–672Google Scholar
  30. 30.
    van Laar JM (2007) Do high levels of IgA rheumatoid factor indicate a poor response to treatment with TNF inhibitors in patients with RA? Nat Clin Pract Rheumatol 3(10):544–545. CrossRefGoogle Scholar
  31. 31.
    Markusse HM, Otten HG, Vroom TM, Smeets TJ, Fokkens N, Breedveld FC (1993) Rheumatoid factor isotypes in serum and salivary fluid of patients with primary Sjogren’s syndrome. Clin Immunol Immunopathol 66(1):26–32CrossRefGoogle Scholar
  32. 32.
    Otten HG, Daha MR, van Laar JM, de Rooy HH, Breedveld FC (1991) Subclass distribution and size of human IgA rheumatoid factor at mucosal and nonmucosal sites. Arthritis Rheum 34(7):831–839CrossRefGoogle Scholar
  33. 33.
    Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, Font J, Ingelmo M (2002) Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81(4):270–280CrossRefGoogle Scholar
  34. 34.
    Koh JH, Lee J, Chung SH, Kwok SK, Park SH (2015) Relation of autoimmune cytopenia to glandular and systemic manifestations in primary Sjogren syndrome: analysis of 113 Korean patients. J Rheumatol 42(10):1817–1824. CrossRefGoogle Scholar
  35. 35.
    Zhao Y, Li Y, Wang L, Li XF, Huang CB, Wang GC, Zhang XW, Zhang ZL, Zhang X, Xiao WG, Dai L, Wang YF, Hu SX, Li HB, Gong L, Liu B, Sun LY, Zhang MJ, Zhang X, Li YZ, Du DS, Zhang SH, Sun YY, Zhang FC (2015) Primary Sjogren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients. Medicine 94(16):e667. CrossRefGoogle Scholar
  36. 36.
    Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, Caporali R (2008) Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 10(3):R51. CrossRefGoogle Scholar
  37. 37.
    Kim SM, Park E, Lee JH, Lee SH, Kim HR (2012) The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjogren syndrome. Rheumatol Int 32(12):3963–3967. CrossRefGoogle Scholar
  38. 38.
    ter Borg EJ, Kelder JC (2016) Polyarthritis in primary Sjogren’s syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up. Clin Rheumatol 35(3):649–655. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kyung-Ann Lee
    • 1
  • Kyoung-Woon Kim
    • 2
  • Bo-Mi Kim
    • 2
  • Ji-Yeon Won
    • 2
  • Han-Ah Kim
    • 3
  • Hee-Won Moon
    • 3
  • Hae-Rim Kim
    • 1
  • Sang-Heon Lee
    • 1
    Email author
  1. 1.Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical CenterKonkuk University School of MedicineSeoulSouth Korea
  2. 2.Convergent Research Consortium for Immunologic DiseaseThe Catholic UniversitySeoulSouth Korea
  3. 3.Department of Laboratory Medicine, Konkuk University Medical CenterKonkuk University School of MedicineSeoulSouth Korea

Personalised recommendations